Sage Rhino Capital LLC Sells 26 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Sage Rhino Capital LLC trimmed its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.8% during the fourth quarter, HoldingsChannel.com reports. The fund owned 658 shares of the medical research company’s stock after selling 26 shares during the period. Sage Rhino Capital LLC’s holdings in Thermo Fisher Scientific were worth $349,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in TMO. Raleigh Capital Management Inc. grew its holdings in shares of Thermo Fisher Scientific by 49.1% during the third quarter. Raleigh Capital Management Inc. now owns 82 shares of the medical research company’s stock worth $41,000 after buying an additional 27 shares in the last quarter. Cedar Mountain Advisors LLC lifted its position in shares of Thermo Fisher Scientific by 107.0% in the fourth quarter. Cedar Mountain Advisors LLC now owns 89 shares of the medical research company’s stock valued at $47,000 after buying an additional 46 shares during the last quarter. Financial Connections Group Inc. acquired a new position in shares of Thermo Fisher Scientific during the 4th quarter worth approximately $53,000. Operose Advisors LLC boosted its position in Thermo Fisher Scientific by 250.0% during the third quarter. Operose Advisors LLC now owns 105 shares of the medical research company’s stock worth $53,000 after purchasing an additional 75 shares during the period. Finally, Valley National Advisers Inc. lifted its stake in shares of Thermo Fisher Scientific by 40.5% during the 3rd quarter. Valley National Advisers Inc. now owns 111 shares of the medical research company’s stock worth $56,000 after buying an additional 32 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of NYSE TMO traded down $8.15 during midday trading on Tuesday, reaching $568.74. 1,514,866 shares of the company were exchanged, compared to its average volume of 1,554,109. The stock has a market cap of $217.09 billion, a P/E ratio of 36.48, a PEG ratio of 2.41 and a beta of 0.80. Thermo Fisher Scientific Inc. has a one year low of $415.60 and a one year high of $603.82. The company has a quick ratio of 1.33, a current ratio of 1.70 and a debt-to-equity ratio of 0.68. The stock’s 50-day moving average price is $574.58 and its 200-day moving average price is $531.67.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, April 24th. The medical research company reported $5.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.70 by $0.41. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. The company had revenue of $10.35 billion during the quarter, compared to the consensus estimate of $10.14 billion. On average, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 21.56 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, April 15th. Investors of record on Friday, March 15th were issued a $0.39 dividend. The ex-dividend date of this dividend was Thursday, March 14th. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 annualized dividend and a yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.01%.

Analysts Set New Price Targets

TMO has been the subject of several research reports. Raymond James raised their price objective on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an “outperform” rating in a research report on Thursday, February 1st. Barclays increased their price objective on Thermo Fisher Scientific from $590.00 to $615.00 and gave the stock an “equal weight” rating in a research report on Thursday, April 25th. JPMorgan Chase & Co. lifted their price objective on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a research note on Thursday, April 25th. Royal Bank of Canada raised their target price on shares of Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an “outperform” rating in a report on Thursday, February 1st. Finally, The Goldman Sachs Group increased their price target on Thermo Fisher Scientific from $550.00 to $640.00 and gave the stock a “buy” rating in a research report on Wednesday, April 10th. Five investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $607.35.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 2,000 shares of the company’s stock in a transaction on Friday, April 26th. The shares were sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the sale, the senior vice president now owns 13,083 shares of the company’s stock, valued at $7,430,359.02. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $555.63, for a total value of $5,556,300.00. Following the transaction, the chief executive officer now owns 49,155 shares of the company’s stock, valued at approximately $27,311,992.65. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Michael A. Boxer sold 2,000 shares of the stock in a transaction that occurred on Friday, April 26th. The stock was sold at an average price of $567.94, for a total value of $1,135,880.00. Following the completion of the sale, the senior vice president now directly owns 13,083 shares of the company’s stock, valued at $7,430,359.02. The disclosure for this sale can be found here. In the last 90 days, insiders sold 52,277 shares of company stock worth $29,649,264. 0.34% of the stock is currently owned by insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.